Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study

Yuji Nakamoto, Kaori Togashi, Tomohiro Kaneta, Hiroshi Fukuda, Kotaro Nakajima, Kazuhiro Kitajima, Koji Murakami, Hirofumi Fujii, Mitsuo Satake, Ukihide Tateishi, Kazuo Kubota, Michio Senda

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume39
Issue number5
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Multicenter Studies
Stomach Neoplasms
Recurrence
Second Primary Neoplasms
Fluorodeoxyglucose F18
Carcinoid Tumor
Tumor Biomarkers
Colonic Neoplasms
Lung Neoplasms

Keywords

  • 18F-FDG
  • Gastric cancer
  • PET
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Nakamoto, Y., Togashi, K., Kaneta, T., Fukuda, H., Nakajima, K., Kitajima, K., ... Senda, M. (2009). Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study. Japanese Journal of Clinical Oncology, 39(5), 297-302. https://doi.org/10.1093/jjco/hyp010

Clinical value of whole-body FDG-PET for recurrent gastric cancer : A multicenter study. / Nakamoto, Yuji; Togashi, Kaori; Kaneta, Tomohiro; Fukuda, Hiroshi; Nakajima, Kotaro; Kitajima, Kazuhiro; Murakami, Koji; Fujii, Hirofumi; Satake, Mitsuo; Tateishi, Ukihide; Kubota, Kazuo; Senda, Michio.

In: Japanese Journal of Clinical Oncology, Vol. 39, No. 5, 2009, p. 297-302.

Research output: Contribution to journalArticle

Nakamoto, Y, Togashi, K, Kaneta, T, Fukuda, H, Nakajima, K, Kitajima, K, Murakami, K, Fujii, H, Satake, M, Tateishi, U, Kubota, K & Senda, M 2009, 'Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study', Japanese Journal of Clinical Oncology, vol. 39, no. 5, pp. 297-302. https://doi.org/10.1093/jjco/hyp010
Nakamoto, Yuji ; Togashi, Kaori ; Kaneta, Tomohiro ; Fukuda, Hiroshi ; Nakajima, Kotaro ; Kitajima, Kazuhiro ; Murakami, Koji ; Fujii, Hirofumi ; Satake, Mitsuo ; Tateishi, Ukihide ; Kubota, Kazuo ; Senda, Michio. / Clinical value of whole-body FDG-PET for recurrent gastric cancer : A multicenter study. In: Japanese Journal of Clinical Oncology. 2009 ; Vol. 39, No. 5. pp. 297-302.
@article{cf958ff0ffc14d86b72963e6c7a92b6a,
title = "Clinical value of whole-body FDG-PET for recurrent gastric cancer: A multicenter study",
abstract = "Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67{\%}) in Group A, in 11 patients (58{\%}) in Group B and in 2 patients (7{\%}) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5{\%}). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81{\%}, 87{\%} and 83{\%}, respectively, in Group A, 73{\%}, 88{\%} and 79{\%}, respectively, in Group B and 50{\%}, 88{\%} and 85{\%}, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48{\%}) in Group A, in 8 patients (42{\%}) in Group B and in 2 patients (7{\%}) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.",
keywords = "18F-FDG, Gastric cancer, PET, Recurrence",
author = "Yuji Nakamoto and Kaori Togashi and Tomohiro Kaneta and Hiroshi Fukuda and Kotaro Nakajima and Kazuhiro Kitajima and Koji Murakami and Hirofumi Fujii and Mitsuo Satake and Ukihide Tateishi and Kazuo Kubota and Michio Senda",
year = "2009",
doi = "10.1093/jjco/hyp010",
language = "English",
volume = "39",
pages = "297--302",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Clinical value of whole-body FDG-PET for recurrent gastric cancer

T2 - A multicenter study

AU - Nakamoto, Yuji

AU - Togashi, Kaori

AU - Kaneta, Tomohiro

AU - Fukuda, Hiroshi

AU - Nakajima, Kotaro

AU - Kitajima, Kazuhiro

AU - Murakami, Koji

AU - Fujii, Hirofumi

AU - Satake, Mitsuo

AU - Tateishi, Ukihide

AU - Kubota, Kazuo

AU - Senda, Michio

PY - 2009

Y1 - 2009

N2 - Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.

AB - Objective: The purpose of this multicenter study was to evaluate the clinical usefulness of positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for suspected recurrent gastric cancer. Methods: We performed a retrospective review of 92 consecutive patients who underwent PET [either integrated PET/computed tomography (CT) or manual fusion of dedicated PET and CT] scans for post-treatment surveillance of gastric cancer between June 2006 and December 2007. Of these patients, 46 patients were suspected of recurrence by other imaging modalities (Group A), 19 patients were suspected of recurrence by tumor markers without definite findings (Group B) and the remaining 27 patients underwent a PET scan without evidence of recurrence (Group C). The diagnostic performance and prevalence of the clinical impact of FDG-PET were analyzed. Results: Recurrence of gastric cancer was confirmed in 31 patients (67%) in Group A, in 11 patients (58%) in Group B and in 2 patients (7%) in Group C. In addition, colon cancer (n = 3), lung cancer (n = 1) and pulmonary carcinoid (n = 1) were identified in five patients (5%). In patient-basis, the sensitivity, specificity and diagnostic accuracy of PET for recurrence were 81%, 87% and 83%, respectively, in Group A, 73%, 88% and 79%, respectively, in Group B and 50%, 88% and 85%, respectively, in Group C. Therapeutic management was influenced by PET results in 22 patients (48%) in Group A, in 8 patients (42%) in Group B and in 2 patients (7%) in Group C, including cases in which PET was helpful for detecting second primary cancer. Conclusions: PET with FDG yielded useful information in patients with suspected recurrent gastric cancer, especially when recurrence was suspected in the clinical setting.

KW - 18F-FDG

KW - Gastric cancer

KW - PET

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=65549094936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549094936&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyp010

DO - 10.1093/jjco/hyp010

M3 - Article

C2 - 19269991

AN - SCOPUS:65549094936

VL - 39

SP - 297

EP - 302

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

ER -